What are the early signs of Stevens-Johnson Syndrome (SJS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Early Signs of Stevens-Johnson Syndrome

The earliest warning signs of Stevens-Johnson Syndrome are a prodromal flu-like illness (fever, malaise, upper respiratory symptoms) followed by cutaneous pain and a painful rash that typically begins on the face, upper torso, and proximal limbs, accompanied by early involvement of mucous membranes (eyes, mouth, nose, genitalia). 1

Prodromal Phase (Days Before Rash)

  • Fever, malaise, and upper respiratory tract symptoms precede the eruption by several days 1
  • Sore throat may be an initial symptom 1
  • Ocular inflammation can develop before skin signs appear 1
  • This prodromal phase typically occurs 4-28 days after starting the culprit medication 2

Early Cutaneous Signs

Cutaneous pain is a prominent and critical early feature that should immediately alert clinicians to incipient epidermal necrolysis 1, 3. This is a key distinguishing feature that warrants urgent evaluation.

Initial Rash Characteristics:

  • Atypical target lesions and/or purpuric macules are the earliest skin lesions 1, 3
  • The rash begins on the upper torso, proximal limbs, and face, then spreads to the trunk and distal limbs 1, 3
  • Lesions appear as dusky, dark red macules with a dark center surrounded by a pink ring 3
  • Tender skin to touch is an early warning sign 1, 3
  • Involvement of palms and soles is often prominent early 1, 3

Early Mucosal Involvement

Mucous membrane involvement of the eyes, mouth, nose, and genitalia is usually an early feature and may precede extensive skin involvement 1, 3:

  • Purulent keratoconjunctivitis with eyelid edema in the eyes 1
  • Painful oral erosions and mouth ulcers 1
  • Genital mucosal involvement 1
  • This erosive and hemorrhagic mucositis is a hallmark early sign 1

Critical Early Physical Findings

  • Positive Nikolsky sign: Gentle lateral pressure on lesional skin causes the epidermis to slide over the dermis, though this is not specific to SJS 1, 4
  • Skin shearing with minimal trauma 1
  • Confluent erythema developing in affected areas 1

Important Clinical Pitfalls

Do not dismiss early symptoms as simple viral illness or drug rash. The combination of fever, painful skin, and mucosal involvement should trigger immediate suspicion 1.

Cutaneous pain out of proportion to visible findings is a red flag that distinguishes early SJS from benign drug eruptions 1, 3.

Differentiation from erythema multiforme major (EMM) is crucial: EMM has typical raised target lesions predominantly on limbs and extremities, while SJS has flat atypical targets more widely distributed on the torso and face 1, 3.

Immediate Action Required

If SJS is suspected, discontinue any potential culprit drug immediately 1. Common high-risk medications include sulfonamide antibiotics, anticonvulsants (carbamazepine, phenytoin, phenobarbital), allopurinol, NSAIDs of the oxicam type, and aminopenicillins 5, 6.

The FDA label for carbamazepine specifically warns that patients should report fever, sore throat, rash, ulcers in the mouth, easy bruising, or lymphadenopathy immediately, as these may signal serious reactions 7.

Early recognition within the first few days is critical, as lesions expand and coalesce rapidly, reaching maximum extent 5-7 days after disease onset 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update.

American journal of clinical dermatology, 2015

Guideline

Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Clinical Characteristics

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.

American journal of clinical dermatology, 2000

Research

Toxic epidermal necrolysis and Stevens-Johnson syndrome.

Orphanet journal of rare diseases, 2010

Research

Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Clinical reviews in allergy & immunology, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.